Table 2.
Life expectancy (LE) and loss-of-LE of the study cohort and lung cancer patients who were smokers.
| Pathology | Stage | Number | Age at diagnosis | Life expectancy (LE) | Loss-of-LE by comparing LE with that of age-, sex-, and calendar year- matched reference population* | Loss-of-LE by comparing LE with that of age-, sex-, calendar year-, and comorbidities-matched referents | |
|---|---|---|---|---|---|---|---|
| Mean (SD) | Life-years (95% CI) | Life-years (95% CI) | Life-years (95% CI) | ||||
| SCLC | Limited | Study cohort | 2176 | 69.2 (7.4) | 2.3 (2.0 to 2.7) | 13.2 (12.6 to 13.8) | 12.5 (11.5 to 13.4) |
| Smokers | 1042 | 68.0 (7.3) | 2.6 (2.0 to 3.2) | 13.8 (13.2 to 14.4) | |||
| Extensive | Study cohort | 5156 | 69.7 (7.3) | 0.8 (0.7 to 0.9) | 14.4 (14.2 to 14.6) | 14.2 (13.6 to 14.8) | |
| Smokers | 2559 | 68.4 (7.2) | 0.8 (0.7 to 0.9) | 15.5 (15.3 to 15.7) | |||
| SqCC | I | Study cohort | 1976 | 70.5 (7.0) | 7.4 (6.7 to 8.1) | 7.2 (6.2 to 8.2) | 6.4 (5.3 to 7.2) |
| Smokers | 893 | 70.1 (6.9) | 6.8 (5.0 to 8.6) | 8.1 (6.3 to 9.9) | |||
| II | Study cohort | 1255 | 70.1 (7.0) | 5.3 (4.7 to 6.6) | 9.5 (8.7 to 10.3) | 8.7 (7.5 to 9.7) | |
| Smokers | 656 | 69.7 (7.1) | 5.7 (4.3 to 7.1) | 9.5 (8.1 to 10.9) | |||
| IIIA | Study cohort | 2175 | 70.5 (7.2) | 2.6 (2.4 to 3.0) | 11.8 (11.2 to 12.4) | 11.8 (11.3 to 12.3) | |
| Smokers | 1033 | 70.0 (7.3) | 2.6 (2.2 to 3.0) | 12.4 (11.8 to 13.0) | |||
| IIIB | Study cohort | 3411 | 70.1 (7.2) | 1.8 (1.6 to 2.1) | 13.1 (12.7 to 13.5) | 12.2 (11.0 to 13.2) | |
| Smokers | 1249 | 69.3 (7.4) | 1.6 (1.4 to 1.8) | 14.0 (13.6 to 14.4) | |||
| IV | Study cohort | 6571 | 70.3 (7.3) | 1.0 (0.9 to 1.1) | 13.9 (13.7 to 14.1) | 13.1 (12.7 to 13.6) | |
| Smokers | 2700 | 69.5 (7.3) | 0.8 (0.7 to 0.9) | 14.5 (14.3 to 14.7) | |||
| Adenocarcinoma | I | Study cohort | 7930 | 67.0 (7.3) | 13.6 (11.7 to 14.4) | 5.2 (4.0 to 6.4) | 4.0 (2.9 to 6.3) |
| IA | 4453 | 66.3 (7.2) | 14.5 (12.6 to 16.4) | 3.7 (1.0 to 5.8) | |||
| IB | 3468 | 67.8 (7.3) | 11.2 (9.9 to 12.7) | 5.9 (3.9 to 7.6) | |||
| Smokers | 1450 | 67.0 (7.1) | 11.0 (8.1 to 13.9) | 6.3 (3.4 to 9.2) | |||
| II | Study cohort | 1587 | 67.6 (7.4) | 6.6 (6.1 to 8.0) | 11.4 (10.4 to 12.4) | 10.8 (9.1 to 11.3) | |
| Smokers | 385 | 67.6 (7.5) | 6.9 (4.7 to 9.1) | 10.0 (7.6 to 12.4) | |||
| IIIA | Study cohort | 2792 | 68.0 (7.6) | 5.2 (4.5 to 6.1) | 12.4 (11.6 to 13.2) | 12.0 (10.8 to 13.4) | |
| Smokers | 640 | 67.6 (7.5) | 4.8 (3.8 to 5.8) | 12.1 (10.9 to 13.3) | |||
| IIIB | Study cohort | 4398 | 69.2 (7.5) | 2.6 (2.4 to 2.8) | 13.8 (13.4 to 14.2) | 13.3 (12.8 to 14.0) | |
| Smokers | 744 | 67.6 (7.7) | 2.5 (2.1 to 2.9) | 14.3 (13.7 to 14.9) | |||
| IV | Study cohort | 28,109 | 68.4 (7.7) | 1.9 (1.8 to 2.1) | 15.4 (15.2 to 15.6) | 15.1 (14.8 to 15.4) | |
| Smokers | 6869 | 67.8 (7.7) | 1.5 (1.3 to 1.7) | 15.3 (15.1 to 15.5) | |||
| Other non-SqCC | I | Study cohort | 852 | 69.6 (7.6) | 9.3 (8.1 to 10.3) | 6.5 (4.9 to 8.1) | 5.4 (4.2 to 7.5) |
| Smokers | 232 | 68.4 (7.2) | 11.2 (7.7 to 14.7) | 5.0 (1.7 to 8.3) | |||
| II | Study cohort | 410 | 69.5 (7.8) | 4.4 (3.6 to 6.4) | 11.4 (10.0 to 12.8) | 10.7 (8.4 to 12.0) | |
| Smokers | 139 | 68.7 (7.8) | 3.9 (1.7 to 6.1) | 12.0 (9.6 to 14.4) | |||
| IIIA | Study cohort | 841 | 70.1 (7.5) | 3.1 (2.6 to 4.0) | 12.3 (11.5 to 13.1) | 11.7 (10.2 to 13.2) | |
| Smokers | 203 | 69.3 (7.2) | 3.3 (1.9 to 4.7) | 12.4 (10.8 to 14.0) | |||
| IIIB | Study cohort | 1622 | 70.3 (7.6) | 1.8 (1.5 to 2.1) | 13.4 (13.0 to 13.8) | 13.4 (12.6 to 14.3) | |
| Smokers | 296 | 69.4 (7.8) | 1.6 (0.8 to 2.4) | 13.9 (12.7 to 15.1) | |||
| IV | Study cohort | 6754 | 70.5 (7.4) | 1.0 (0.9 to 1.1) | 14.1 (13.9 to 14.3) | 14.5 (14.0 to 15.0) | |
| Smokers | 1469 | 69.7 (7.7) | 0.7 (0.6 to 0.8) | 14.7 (14.3 to 15.1) | |||
SCLC small-cell lung cancer, SqCC squamous-cell non-small-cell lung cancer.
* Smoking information of lung cancer patients was available from 2011, the follow-up period was too short to estimate the lifetime survival functions of age-, sex-, calendar year-, and comorbidities-matched referents accurately. Survival of lung cancer patients was directly compared with that of age-, sex-, calendar year-matched reference population simulated from the life tables for loss-of-LE. We also applied the method to the study cohort for comparison.